Evidence & regulatory context
- Mechanism
- miR-124-3p agomir; microRNA mimic oligonucleotide.
- Target
- Not recorded
- Injury models
- Endotoxin/LPS
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MixedEndotoxin/LPSMale
Model: Lipopolysaccharide-induced acute respiratory distress syndrome
miR-124-3p expression fell after LPS exposure; agomir treatment attenuated alveolar haemorrhage and interstitial oedema, reduced IL-1beta, IL-6 and TNF-alpha, and suppressed p65 expression and apoptosis.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
